Cytophage Technologies Ltd. (V:CYTO)
Business Focus: Pharmaceuticals (NEC)
Apr 30, 2024 05:30 am ET
Cytophage Announces Fiscal Year End 2023 Results
Winnipeg, April 30, 2024. Cytophage Technologies Ltd.
(TSXV:CYTO) (“Cytophage” or the
“Company”), the only publicly traded phage company
that is focused on bacteriophage solutions for both animal health and
human health, today released its fiscal
year end results for the year ending December 31st, 2023.
Cytophage’s audited financial statements and the Management
Discussion and Analysis Report are available under the Company’s
profile at sedarplus.com.
Apr 16, 2024 05:50 am ET
Cytophage Appoints New Board Director
Winnipeg – TheNewswire
- April 16, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the
“Company”) is pleased to announce that Michael D. Cochrane, a
managing partner at Dixford Capital, LLC, has joined the Cytophage
board of directors as its newest member. He will also join the Audit
and Finance Committee of the board. Michael’s extensive experience
as an investment banking veteran complements the board’s wealth of
expertise in research, product development, commercialization, finance
and corporate governance.
Apr 02, 2024 05:50 am ET
Cytophage Provides Update on Bacteriophage Human Trial at The Ottawa Hospital
Winnipeg – TheNewswire
- [April 2nd, 2024]. Cytophage Technologies Ltd.
(TSXV:CYTO) (“Cytophage” or the “Company”) is pleased
to provide an interim update on the recently completed human trial at The
Ottawa Hospital where Cytophage bacteriophages were used to treat a patient with an
antibiotic-resistant prosthetic joint infection (see press release from March 1st,
2024). The patient had previously undergone 15
surgeries and was facing the potential amputation of her leg at the
waist. She was treated
with Cytophage phages for several weeks, via both direct injection and
through an IV line, and
Mar 01, 2024 06:50 am ET
Cytophage Provides Bacteriophages for Landmark Treatment of Joint Replacement Infection in Canada
Winnipeg – TheNewswire -
March 1, 2024 — Cytophage Technologies Ltd. (“Cytophage” or the
“Company”) (TSXV:CYTO) is pleased to announce that it is
collaborating with infectious diseases clinician-scientist, Dr. Marisa
Azad (Principal Investigator), at The Ottawa Hospital to deliver –
for the first time in Canada – bacteriophage (phage) therapy to a
patient suffering from a severe hardware-associated bone and joint
infection, with approval from Health Canada and The Ottawa Hospital
Research Institute.
Feb 12, 2024 06:50 am ET
Cytophage Update on Upcoming Product for Egg Production in Canada
Winnipeg – TheNewswire - February 12, 2024 -
Cytophage Technologies Ltd. (TSXV:CYTO)
(“Cytophage” or the “Company”) is pleased to announced that it
has completed research and development of its OvaPhage product, and is
preparing to conduct field trials in Canada as a final step before
commercialization. Cytophage has been in longstanding discussions
with Canadian industry leaders who have sought alternatives to the
currently available disinfectant products used in egg production. As
a result, Cytophage has developed OvaPhage,
its next product in the FarmPhage line. OvaPhage is a
bacteriop
Feb 07, 2024 06:30 pm ET
Cytophage Technologies Ltd. Announces First Day of Trading
Winnipeg, MB – TheNewswire -- February 7, 2024 – Cytophage Technologies Ltd.
(“Cytophage” or the “Company”) (TSXV:CYTO) (formerly Cuspis
Capital III Ltd. (“Cuspis”) (TSXV:CIII.P)) is pleased to announce that it has received its final bulletin from the
TSX Venture Exchange Inc. (the “TSXV”), and is scheduled to
commence trading on February 9th, 2024.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.